爵士制药 JAZZ 深 沪
等待开盘 10-02 09:30:00 美东时间
136.71
+4.910
+3.73%
华盛通- 最 高137.50
- 今 开131.78
- 成交量 49.40万股
- 最 低 131.76
- 昨 收 131.80
- 总市值 82.72亿
- 52周最高 148.0568
- 市盈率 静 15.81
- 换手率 0.82%
- 52周最低 95.49
- 委 比 -85.25%
- 总股本 6051.10万
- 历史最高 194.73
- 量 比 1.07
- 振 幅 4.36%
- 历史最低 31.87
- 每 手 1
- 风险率 10.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
In the preceding three months, 9 analysts have released ratings for Jazz Pharma...
09-24 22:01
Jazz Pharma's Xywav Shows Phase 4 Results Improving Sleep And Daytime Alertness In Narcolepsy, Hypersomnia Patients
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav® (calcium, magnesium, potassium, and sodium oxybates)
09-22 19:46
Jazz Pharmaceuticals’ ZW25 Study Update: A Potential Game-Changer in Cancer Treatment
Jazz Pharmaceuticals (($JAZZ)) announced an update on their ongoing clinical st...
09-13 00:30
Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem
Amneal Pharmaceuticals (NASDAQ:AMRX) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its generic product targeting Jazz Pharmaceuticals’ (NASDAQ:JAZZ) sleep disorder th...
09-11 23:56
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Amneal Pharmaceuticals近日宣布其Sodium oxybate口服溶液500 mg/mL仿制药获得美国FDA批准，该药参考Jazz Pharmaceuticals的Xyrem，用于治疗7岁及以上narcolepsy患者的cataplexy或过度日间嗜睡。这是FDA批准的首个Sodium oxybate仿制药，将扩大Amneal平价药品系列，并提升患者获得治疗的机会。Sodium oxybate作为narcolepsy的标准治疗药物，可改善夜间睡眠并显著减少cataplexy发作。Amneal此举将为患者、医疗提供者和支付方提供更实惠的选择。
09-11 12:00
Jazz Pharma's Modeyso Earns NCCN Category 2A Recommendation For Treating H3 K27M-Mutant High-Grade Glioma In Pediatric And Adult Patients
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United StatesJazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Modeyso™ (dordaviprone)
09-09 19:48
Kohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($KSS) ), ( ($BILL) ), ( ($NVAX) ),...
08-30 17:01
美股大行评级 | 英伟达、Snowflake、Five Below、Pure Storage等公司获多家大行集体上调目标价
今日重点评级关注：摩根大通：维持Futu Holdings"超配"评级，目标价从200美元升至270美元；Craig-Hallum：维持英伟达"买入"评级，目标价从195美元升至245美元
08-29 09:47
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $205
Truist Securities analyst Gregory Fraser maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $200 to $205.
08-28 20:55
